This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Jul 1;9(7):928-929.

doi: 10.1001/jamaoncol.2023.0759.

MGMT Methylation Status in Grades 2 and 3 Gliomas Is Important, but Is It Prognostic?

Kelli B Pointer¹, Na Tosha N Gatson²

Affiliations

Affiliations

¹ Dartmouth Cancer Center, Dartmouth Geisel School of Medicine, Radiation Oncology, Lebanon, New Hampshire.
² Banner MD Anderson Cancer Center, University of Arizona Medical School, Neuro-oncology, Phoenix.

PMID: 37200043
DOI: 10.1001/jamaoncol.2023.0759

Comment

MGMT Methylation Status in Grades 2 and 3 Gliomas Is Important, but Is It Prognostic?

Kelli B Pointer et al. JAMA Oncol. 2023.

. 2023 Jul 1;9(7):928-929.

doi: 10.1001/jamaoncol.2023.0759.

Authors

Kelli B Pointer¹, Na Tosha N Gatson²

Affiliations

¹ Dartmouth Cancer Center, Dartmouth Geisel School of Medicine, Radiation Oncology, Lebanon, New Hampshire.
² Banner MD Anderson Cancer Center, University of Arizona Medical School, Neuro-oncology, Phoenix.

PMID: 37200043
DOI: 10.1001/jamaoncol.2023.0759

No abstract available

PubMed Disclaimer

Comment on

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC. Kinslow CJ, et al. JAMA Oncol. 2023 Jul 1;9(7):919-927. doi: 10.1001/jamaoncol.2023.0990. JAMA Oncol. 2023. PMID: 37200021 Free PMC article.

Similar articles

Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW. Kim HS, et al. Pathol Res Pract. 2018 Jun;214(6):881-888. doi: 10.1016/j.prp.2018.04.002. Epub 2018 Apr 5. Pathol Res Pract. 2018. PMID: 29650441
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas.
Zhao B, Qi H, Ma W. Zhao B, et al. JAMA Oncol. 2023 Dec 1;9(12):1734-1735. doi: 10.1001/jamaoncol.2023.4736. JAMA Oncol. 2023. PMID: 37856142 No abstract available.
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas-Reply.
Kinslow CJ, Cheng SK, Wang TJC. Kinslow CJ, et al. JAMA Oncol. 2023 Dec 1;9(12):1735-1736. doi: 10.1001/jamaoncol.2023.4754. JAMA Oncol. 2023. PMID: 37856114 No abstract available.
The significance of MGMT methylation in Glioblastoma Multiforme prognosis.
Rao AM, Quddusi A, Shamim MS. Rao AM, et al. J Pak Med Assoc. 2018 Jul;68(7):1137-1139. J Pak Med Assoc. 2018. PMID: 30317322 Review.
Prognostic markers in gliomas.
Labussiere M, Wang XW, Idbaih A, Ducray F, Sanson M. Labussiere M, et al. Future Oncol. 2010 May;6(5):733-9. doi: 10.2217/fon.10.25. Future Oncol. 2010. PMID: 20465388 Review.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program